Julie Cahu
YOU?
Author Swipe
View article: Supplementary Figure Legend from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes
Supplementary Figure Legend from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes Open
PDF file - 64K
View article: Data from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes
Data from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes Open
Purpose: Clinical responses to the immmunomodulatory drug lenalidomide have been observed in patients with relapsed/refractory mantle cell lymphoma (MCL), although its mechanism of action remains partially unknown. We investigated w…
View article: Supplementary Methods from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes
Supplementary Methods from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes Open
PDF file - 78K
View article: Supplementary Methods from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes
Supplementary Methods from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes Open
PDF file - 78K
View article: Data from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes
Data from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes Open
Purpose: Clinical responses to the immmunomodulatory drug lenalidomide have been observed in patients with relapsed/refractory mantle cell lymphoma (MCL), although its mechanism of action remains partially unknown. We investigated w…
View article: Supplementary Figure 3 from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes
Supplementary Figure 3 from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes Open
PDF file - 3780K, (A) Accumulation of p27KIP1 and activated capase-3 in cytosol-enriched protein extracts from Rec-1 cells cultured for 72 h with 1 μmol/L lenalidomide and subjected to a Human apoptosis antibody array (R&D Systems).
View article: Supplementary Figure 1 from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes
Supplementary Figure 1 from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes Open
PDF file - 1473K, Recounting of cells with nuclear positivity for cyclin D1 and p27KIP1 in (A) tumor specimen from two MCL patients presenting with a classical (Pt#1) or a blastoid (Pt#3)subtype and (B) in 6 MCL cell lines from either high…
View article: Supplementary Figure 3 from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes
Supplementary Figure 3 from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes Open
PDF file - 3780K, (A) Accumulation of p27KIP1 and activated capase-3 in cytosol-enriched protein extracts from Rec-1 cells cultured for 72 h with 1 μmol/L lenalidomide and subjected to a Human apoptosis antibody array (R&D Systems).
View article: Supplementary Figure Legend from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes
Supplementary Figure Legend from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes Open
PDF file - 64K
View article: Supplementary Figure 2 from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes
Supplementary Figure 2 from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes Open
PDF file - 6167K, (A) Flow cytometry analysis of cyclin D1 and p27KIP1 intracellular levels in a set of primary MCL samples (n=10, Table 1). In gray, isotypic control curves; in black, cyclin D1 and p27KIP1 curves. r indicates x-mean cycli…
View article: Supplementary Figure 2 from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes
Supplementary Figure 2 from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes Open
PDF file - 6167K, (A) Flow cytometry analysis of cyclin D1 and p27KIP1 intracellular levels in a set of primary MCL samples (n=10, Table 1). In gray, isotypic control curves; in black, cyclin D1 and p27KIP1 curves. r indicates x-mean cycli…
View article: Supplementary Figure 1 from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes
Supplementary Figure 1 from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes Open
PDF file - 1473K, Recounting of cells with nuclear positivity for cyclin D1 and p27KIP1 in (A) tumor specimen from two MCL patients presenting with a classical (Pt#1) or a blastoid (Pt#3)subtype and (B) in 6 MCL cell lines from either high…
View article: HIF-1α and rapamycin act as gerosuppressant in multiple myeloma cells upon genotoxic stress
HIF-1α and rapamycin act as gerosuppressant in multiple myeloma cells upon genotoxic stress Open
Multiple myeloma (MM) is still an incurable hematological malignancy. Despite recent progress due to new anti-myeloma agents, the pathology is characterized by a high frequency of de novo or acquired resistance. Delineating the mechanisms …
View article: HIF-1α and rapamycin act as gerosuppressant in multiple myeloma cells upon genotoxic stress
HIF-1α and rapamycin act as gerosuppressant in multiple myeloma cells upon genotoxic stress Open
Multiple myeloma (MM) is still an incurable hematological malignancy. Despite recent progress due to new anti-myeloma agents, the pathology is characterized by a high frequency of de novo or acquired resistance. Delineating the mech…
View article: HIF-1<b>α</b> and rapamycin act as gerosuppressant in multiple myeloma cells upon genotoxic stress
HIF-1<b>α</b> and rapamycin act as gerosuppressant in multiple myeloma cells upon genotoxic stress Open
Multiple myeloma (MM) is still an incurable hematological malignancy. Despite recent progress due to new anti-myeloma agents, the pathology is characterized by a high frequency of de novo or acquired resistance. Delineating the mech…
View article: HIF-1α and rapamycin act as gerosuppressant in multiple myeloma cells upon genotoxic stress
HIF-1α and rapamycin act as gerosuppressant in multiple myeloma cells upon genotoxic stress Open
Multiple myeloma (MM) is still an incurable hematological malignancy. Despite recent progress due to new anti-myeloma agents, the pathology is characterized by a high frequency of de novo or acquired resistance. Delineating the mech…
View article: Heat shock factor 1 is a potent therapeutic target for enhancing the efficacy of treatments for multiple myeloma with adverse prognosis
Heat shock factor 1 is a potent therapeutic target for enhancing the efficacy of treatments for multiple myeloma with adverse prognosis Open
View article: Cyclin D1 sensitizes myeloma cells to endoplasmic reticulum stress-mediated apoptosis by activating the unfolded protein response pathway
Cyclin D1 sensitizes myeloma cells to endoplasmic reticulum stress-mediated apoptosis by activating the unfolded protein response pathway Open
The ER is well known to be a crucial regulator of plasma cell death and it plays the same role in their malignant counterparts, myeloma cells. This role involves activation of the UPR controlled at least in part by cyclin D1.
View article: New biomarkers for early diagnosis of Lesch-Nyhan disease revealed by metabolic analysis on a large cohort of patients
New biomarkers for early diagnosis of Lesch-Nyhan disease revealed by metabolic analysis on a large cohort of patients Open